✨ Your Portfolio is fetched and updated from zerodha.
Large Pharmaceuticals

Zydus Lifesciences Ltd.

ZYDUSLIFE

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹1,04,130 Cr.
P/E
22.77

Zydus Lifesciences Ltd.

  • Zydus Lifesciences
  • Mankind Pharma
  • Dr. Reddy's Lab
  • TJI Pharma

FAQs on Zydus Lifesciences Ltd. Shareprice

Zydus Lifesciences has given better returns compared to its competitors.
Zydus Lifesciences has grown at ~26.76% over the last 2yrs while peers have grown at a median rate of 21.73%

Zydus Lifesciences is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Zydus Lifesciences is 22.77, while 3 year average PE is 21.47.
Also latest EV/EBITDA of Zydus Lifesciences is 14.99 while 3yr average is 15.58.

View FAQ's On Business

Growth Table

  • Zydus Lifesciences Ltd.
  • Mankind Pharma
  • Dr. Reddy's Lab

Balance Sheet

  • Zydus Lifesciences Ltd.
  • Mankind Pharma
  • Dr. Reddy's Lab

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Zydus Lifesciences Ltd.
  • Mankind Pharma
  • Dr. Reddy's Lab

Cash Flow

  • Zydus Lifesciences Ltd.
  • Mankind Pharma
  • Dr. Reddy's Lab

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Zydus Lifesciences Ltd.
  • Mankind Pharma
  • Dr. Reddy's Lab

Quarterly Results

  • Zydus Lifesciences Ltd.
  • Mankind Pharma
  • Dr. Reddy's Lab

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Zydus Lifesciences Ltd. Financials

Balance sheet of Zydus Lifesciences is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Zydus Lifesciences is decreasing.
Latest net debt of Zydus Lifesciences is -₹2,743.5 Crs as of Mar-25.
This is less than Mar-24 when it was -₹1,441.1 Crs.

Yes, profit is increasing.
The profit of Zydus Lifesciences is ₹4,638 Crs for TTM, ₹4,526 Crs for Mar 2025 and ₹3,860 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Zydus Lifesciences latest dividend payout ratio is 24.45% and 3yr average dividend payout ratio is 21.08%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech